What's in MinaPharm Pharmaceuticals's pipeline?

MinaPharm Pharmaceuticals has 10 drugs in our index: 10 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with MinaPharm Pharmaceuticals's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Bayer, Boehringer Ingelheim, Estetra, French National Agency for Research on AIDS and Viral Hepatitis.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/minapharm-pharmaceuticals.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

MinaPharm Pharmaceuticals — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MinaPharm Pharmaceuticals pipeline: 10 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

10 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bon one in Arm 3	Bon one in Arm 3	marketed
Xerovirinc in Arm 2	Xerovirinc in Arm 2	marketed
Ciprodiazole	Ciprodiazole	marketed			Other
Ursoplus	Ursoplus	marketed			Other
UDCA 250mg	UDCA 250mg	marketed
Ribavirin in Arm 1	Ribavirin in Arm 1	marketed	Nucleoside analog antiviral	Viral RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)	Virology/Infectious Disease
r-Hirudin	r-Hirudin	marketed	Direct thrombin inhibitor	Thrombin (Factor IIa)	Cardiovascular
Reiferon Retard in Arm 1	Reiferon Retard in Arm 1	marketed	Interferon alfa-2a (long-acting/sustained-release)	Type I interferon receptor (IFNAR)	Oncology, Virology
Ciprofloxacin Tablets & Metronidazole tablets	Ciprofloxacin Tablets & Metronidazole tablets	marketed	Fluoroquinolone + Nitroimidazole antibiotic combination	Bacterial DNA gyrase, topoisomerase IV (ciprofloxacin); anaerobic DNA (metronidazole)	Infectious Disease
Reiferon retard	Reiferon retard	marketed	Interferon alfa-2a (long-acting/sustained-release formulation)	Type I interferon receptor (IFNAR)	Oncology, Virology/Infectious Disease

Therapeutic area mix

Other · 2
Cardiovascular · 1
Infectious Disease · 1
Oncology, Virology · 1
Oncology, Virology/Infectious Disease · 1
Virology/Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Bayer · 1 shared drug class
Boehringer Ingelheim · 1 shared drug class
Estetra · 1 shared drug class
French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
Göteborg University · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MinaPharm Pharmaceuticals:

Cite this brief

Drug Landscape (2026). MinaPharm Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/minapharm-pharmaceuticals. Accessed 2026-06-10.